/sup 131/I-metaiodobenzylguanidine treatment of malignant pheochromocytomas

Conference · Sun Jan 01 04:00:00 EST 1984 · J. Nucl. Med.; (United States)

OSTI ID:6842487

Sisson, J; Shapiro, B; Glowniak, J; Beierwalters, W; Mangner, T; Wieland, D; Carey, J; Petry, N; Copp, J; Eyre, P

When /sup 131/I-metaiodobenzylguanidine (/sup 131/I-MIBG) concentrates in malignant pheochromocytomas, therapeutic radiation can be delivered from within these tumors. Ten patients have now received 1-5 therapies (97-215 mCi/therapy, up to 628 mCi total) for malignant pheochromocytomas. Results in the first 5 patients gave encouragement: 2 had subjective (disappearance of clinical features of disease) and objective (reduction of catecholamine excretion by more than 50%, and of tumor size by more than 70%) benefits. One responding patient developed a new tumor on scintigraphy; a fifth treatment caused regression of the new abnormality and preserved the attained benefits. The other 3 patients have shown little or no response despite additional (third) treatments in 2. Three of the next 5 patients have responded beneficially to /sup 131/I-MIBG. One (208 mCi) and two (197 and 169 mCi) doses in separate patients resulted in: disappearance of symptoms and a diminution of catecholamine excretion (by more than 50% in one and to almost normal levels in the other); but the boney sites made changes in volume of tumors difficult to measure. In an asymptomatic patient, 130 mCi reduced her catecholamine excretion by 33%, but volumes of her liver tumors remain unchanged as yet. One patient had no change after two doses (207 and 167 mCi), and one patient's disease progressed unabated after 186 mCi. In addition to uptake and retention of /sup 131/I-MIBG by tumors, other factors must also determine responses. Moderate leukopenia in two patients has been the only adverse effect. The authors conclude that /sup 131/I-MIBG offers hope to patients with heretofore resistant malignant pheochromocytomas.

• Research Organization: Univ. of Michigan, Ann Arbor, MI
• OSTI ID: 6842487
• Report Number(s): CONF-840619-
• Conference Information: Journal Name: J. Nucl. Med.; (United States) Journal Volume: 25:5
• Country of Publication: United States
• Language: English

Related Subjects

550604* -- Medicine-- Unsealed Radionuclides in Therapy-- (1980-)
62 RADIOLOGY AND NUCLEAR MEDICINE
AMINES
AROMATICS
BETA DECAY RADIOISOTOPES
BETA-MINUS DECAY RADIOISOTOPES
BODY
CARBONIC ACID DERIVATIVES
CARCINOMAS
CATECHOLAMINES
CLEARANCE
COUNTING TECHNIQUES
DAYS LIVING RADIOISOTOPES
DIAGNOSTIC TECHNIQUES
DIGESTIVE SYSTEM
DISEASES
EXCRETION
GLANDS
GUANIDINES
HYDROXY COMPOUNDS
INTERMEDIATE MASS NUCLEI
IODINE 131
IODINE ISOTOPES
ISOTOPES
LIVER
MEDICINE
NEOPLASMS
NUCLEAR MEDICINE
NUCLEI
ODD-EVEN NUCLEI
ORGANIC COMPOUNDS
ORGANIC NITROGEN COMPOUNDS
ORGANS
PATIENTS
PHENOLS
POLYPHENOLS
RADIOISOTOPE SCANNING
RADIOISOTOPES
RADIOLOGY
RADIOTHERAPY
SCINTISCANNING
THERAPEUTIC USES
THERAPY
USES